Savara (SVRA) AI Stock Analysis

• Market Cap: $555.88M
• Dividend Yield: N/A
• Average Volume (3M): 1.18M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.04
• Revenue Growth: N/A
• EPS Growth: -44.25%
• Country: US
• Employees: 59
• Sector: Healthcare
• Sector Strength: 64
• Industry: Biotechnology
• EPS (TTM): -0.48
• Shares Outstanding: 172,633,130
• 10 Day Avg. Volume: 680,100
• 30 Day Avg. Volume: 1,178,410
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -5.30
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $7.10
• Price Target Upside: 118.46% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

Savara's stock score reflects a company in the developmental stage, with significant financial risks due to its lack of revenue and ongoing cash burn. However, a strong balance sheet and recent financing developments provide some stability. Technical indicators suggest short-term positive momentum, but valuation remains challenging with a negative P/E ratio. The recent loan agreement is a positive step, potentially facilitating future growth and commercialization efforts.

Positive Factors

Financial Stability

SVRA had $219M in cash, providing a financial runway through 2Q27, and the debt deal with Hercules gives the company breathing room for the early launch.

Market Potential

Molbreevi is expected to be a blockbuster product with potential peak sales of about $1.2B.

Regulatory Approval

Analysts are highly confident in Molbreevi's regulatory approval due to positive Phase III data showing benefits on lung function.

Negative Factors

Diagnosis Challenges

APAP can be misdiagnosed with similar symptoms to pneumonia, bronchitis, or asthma, resulting in delayed accurate diagnosis.

Regulatory Timing

The completion of Molbreevi's rolling BLA submission sets up a potential PDUFA in late November or early December, creating uncertainty in approval timing.

Savara Business Overview & Revenue Model

Company Description

Savara Inc. (SVRA) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare respiratory diseases. The company's primary therapeutic area includes conditions such as pulmonary alveolar proteinosis (PAP) and idiopathic pulmonary fibrosis (IPF). Savara's lead product candidate is Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), which is currently in clinical development for the treatment of PAP.

How the Company Makes Money

As a clinical-stage biopharmaceutical company, Savara Inc. does not generate revenue from product sales. Instead, the company primarily relies on funding through equity offerings, grants, and strategic partnerships to finance its research and development activities. Significant partnerships with research institutions and pharmaceutical companies may also provide financial support and resources necessary for clinical trials and drug development. Once regulatory approval for its product candidates is obtained, Savara aims to monetize through product sales, licensing agreements, and potential collaborations for commercialization.

Savara Financial Statement Overview

Summary

Savara is in a typical developmental stage for a biotech company, with no revenue and consistent losses as it invests heavily in R&D. While the balance sheet is strong, with substantial equity and cash reserves, the income statement and cash flow highlight the risks of ongoing cash burn and the need for continued external financing. Investors should be aware of the potential for future dilution and the importance of achieving revenue milestones to improve financial health.

Income Statement

Savara's income statement reveals a challenging financial position, with no revenue generation over the past years. Consistent negative EBIT and net income figures indicate ongoing losses, which is common in early-stage biotech firms focused on R&D. The lack of revenue growth and profitability reflects the company's current unprofitable operations.

Balance Sheet

The balance sheet shows a relatively strong equity position compared to liabilities, with a debt-to-equity ratio of 0.16 in 2024, suggesting low leverage. However, the company’s equity ratio of 80.5% indicates a strong reliance on equity financing, which is a positive sign for stability. The company's cash position is robust, providing a cushion for operations despite ongoing losses.

Cash Flow

The cash flow statement reflects negative free cash flow, indicating the company is burning through cash without generating enough income to cover its expenditures. However, significant financing inflows show the company's ability to secure funding, which is essential for sustaining operations. The absence of positive free cash flow growth underscores challenges in achieving operational cash flow sufficiency.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	257.00K
	Gross Profit
0.00	-44.26M	-167.00K	-367.00K	221.96K
	EBIT
-103.20M	-60.01M	-38.84M	-41.48M	-49.30M
	EBITDA
-103.07M	-59.13M	-37.90M	-40.37M	-47.44M
	Net Income Common Stockholders
-95.88M	-54.70M	-38.95M	-45.30M	-51.10M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
196.33M	162.32M	125.88M	161.17M	82.19M
	Total Assets
212.88M	177.56M	139.78M	176.60M	97.75M
	Total Debt
26.62M	26.49M	26.14M	25.79M	25.28M
	Net Debt
11.49M	-94.00K	-25.96M	-8.22M	2.40M
	Total Liabilities
41.43M	37.19M	32.00M	32.10M	33.36M
	Stockholders Equity
171.45M	140.37M	107.78M	144.50M	64.38M
Cash Flow		Free Cash Flow
-89.11M	-51.36M	-34.56M	-40.14M	-43.13M
	Operating Cash Flow
-89.09M	-51.06M	-34.55M	-40.08M	-39.84M
	Investing Cash Flow
-39.94M	-57.12M	52.65M	-69.46M	9.05M
	Financing Cash Flow
117.58M	82.78M	87.00K	120.81M	3.69K

Savara Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.25
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SVRA, the sentiment is Positive. The current price of 3.25 is above the 20-day moving average (MA) of 2.89, above the 50-day MA of 2.76, and below the 200-day MA of 3.50, indicating a neutral trend. The MACD of 0.10 indicates Negative momentum. The RSI at 66.06 is Neutral, neither overbought nor oversold. The STOCH value of 89.57 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SVRA.

Savara Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NAGE	71 Outperform	$535.70M	68.28	22.94%	―	19.18%	―
ARVN	52 Neutral	$614.82M	―	-35.41%	―	-39.92%	7.38%
Sector *	51 Neutral	$5.20B	3.26	-40.34%	2.93%	17.68%	1.94%
URGN	48 Neutral	$463.25M	―	-452.20%	―	9.29%	13.49%
SVRA	46 Neutral	$555.88M	―	-61.50%	―	―	-44.25%
BCYC	46 Neutral	$602.91M	―	-29.06%	―	30.27%	44.12%
KURA	44 Neutral	$509.71M	―	-42.91%	―	―	2.90%

Savara Corporate Events

Savara Secures $200 Million Loan Agreement with Hercules

On March 26, 2025, Savara announced a loan agreement with Hercules Capital for up to $200 million, aimed at strengthening its financial position following the submission of a Biologics License Application to the FDA for MOLBREEVI, a potential first-in-class therapy for aPAP. The agreement includes an initial $30 million to refinance existing debt, with additional funds contingent on FDA approval and other milestones, supporting Savara’s efforts to commercialize MOLBREEVI in the U.S. and Europe.